Aman Kumar Sah

Aman Kumar Sah

Auto-generated profile, based on publicly available information

Aman Kumar Sah

Pokhara University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2024 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
SDShreya Dhungana
Shreya Dhungana
NPNabin Pathak
Nabin Pathak
BBBijaya Basyal
Bijaya Basyal
ASAman Kumar Sah
Aman Kumar Sah
APAnjali Pandit
Anjali Pandit
RKRenu Karki
Renu Karki
The role of clinical pharmacists or oncology pharmacists in pediatric oncology has been established as important in anticancer regimen review, dose calculation, recommendation, chemocounseling, identification of drug-related problems, its resolution, and, prevention and monitoring of adverse drug reactions within high-income countries. With several hospitals providing pediatric oncology services in Nepal, clinical pharmacist involvement in these hospitals is very poor. Upon reviewing the reputed organization and association focused on pediatric oncology pharmacy practice, it looks imperative for Nepal to initiate clinical pharmacy services which will further help in improving patient health outcomes. As such in this commentary, we try to accentuate the pediatric oncology services and pediatric pharmacy practice within Nepal and try to pinpoint the potential areas for clinical pharmacists to focus if they intend to provide services in pediatric oncology pharmacy practice.

1 December 2025 in Integrated Pharmacy Research and Practice
Verified
Journal Article
Open access
NPNabin Pathak
Nabin Pathak
SBSachita Barma
Sachita Barma
Prabhat Kumar JhaPrabhat Kumar Jha
Prabhat Kumar Jha
PSPrerana Shrestha
Prerana Shrestha
UYUjjwal Yadav
Ujjwal Yadav
SSSunil Shrestha
Sunil Shrestha
Along with the positive development in health services and facilities, hospital pharmacy practice in Nepal has also evolved. The minimum service standards (MSS) developed by the Ministry of Health and Population of Nepal act as a structured framework to assess hospitals' readiness and capacity to deliver quality health services and consist of three significant domains: governance and management standards, clinical service management standards, and support service standards. The clinical service management standards also consist of the hospital pharmacy service standards of practice checklist. This study presents a perspective review of MSS checklists and their implications for pharmacy services, where we discuss how the MSS checklist acts as a viable tool for strengthening the hospital pharmacy practice in Nepal's primary, secondary, and tertiary hospitals. Following the MSS checklist, hospital administration, hospital leaders, hospital management committee, and the hospital pharmacy and therapeutic committee can help to develop further action plans to mitigate issues, thus resulting in 100% compliance with the checklist and quality improvement. This paper can also serve as evidence or a start-up for conducting MSS-based research at the provincial and federal levels to inform hospital pharmacy-based practices among the policy-related institutions in the coming days.

17 October 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ASAman Kumar Sah
Aman Kumar Sah
RPRoshan Prajapati
Roshan Prajapati
NPNabin Pathak
Nabin Pathak
SPSushil Panta
Sushil Panta
SGShila Gurung
Shila Gurung
Introduction: Breast cancer is the leading cancer among women globally, and its management typically involves surgery, radiotherapy, and chemotherapy. This combination of complex treatment increases the risk of drug-related problems (DRPs), which can negatively impact the quality of life as it prolongs the hospital stays, increases healthcare costs, and leads to morbidity and mortality. Research on DRPs in the context of breast cancer patients in Nepal is limited; therefore, this study aimed to identify DRPs, assess their prevalence, and examine their associated factors, while emphasizing the importance of pharmaceutical care. Methods: A cross-sectional study was conducted at Bhaktapur Cancer Hospital, Nepal, from February to May 2024. The medical records of 92 patients were reviewed to identify DRPs using the Pharmaceutical Care Network Europe V9.1 tool, along with related scientific literatures and evidence-based guidelines, and verified by two independent medical oncologists. Descriptive statistics were used to summarize the patient characteristics, while the chi-square test was used to evaluate the associations between socio-demographic and clinical characteristics with the presence of DRPs, with a p-value <0.05 considered statistically significant. Results: DRPs were identified in 91 of 92 patients (98.9%), totaling 104 events. Most DRPs (87.5%) concerned treatment safety, while 12.5% involved treatment effectiveness. Patient-related factors (43.4%) and drug selection (33.3%) were primary causes. Common adverse effects included alopecia (88.0%) and anorexia (84.8%). A significant association was observed between adverse drug reactions (ADRs) and DRPs (Fisher’s exact p-value = 0.011). Conclusion: DRPs were highly prevalent among breast cancer patients, mainly due to safety issues, with ADRs significantly contributing to it. Findings highlight the need for larger multicentric and cohort studies, and integration of oncology pharmacy services to optimize pharmaceutical care and minimize DRPs.

4 April 2026 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
NPNabin Pathak
Nabin Pathak
BBBijaya Basyal
Bijaya Basyal
SDShreya Dhungana
Shreya Dhungana
ASAman Kumar Sah
Aman Kumar Sah
RSRajeev Shrestha
Rajeev Shrestha
RKRenu Karki
Renu Karki
Background: Pediatric patients undergoing chemotherapy often need to take multiple medications. Consequently, they may experience drug-related problems (DRPs), including adverse drug reactions, drug interactions, and various medication errors. Methods: A prospective observational study was conducted over three months in the Pediatric Haemato-oncology department of a cancer specialty hospital of Nepal following ethical approval. DRPs were identified from patient medical records and the literature and, recorded according to the Pharmaceutical Care Network Europe V9.1 tool. Data were collected and analyzed using IBM SPSS Statistics V20 and Microsoft Excel 2013 to present the findings. Results: Among the 30 enrolled patients, 211 DRPs were identified in 28 patients (93.3%), averaging 7.5 DRPs per patient, all validated through case-by-case review. Treatment safety was the predominant DRP type (n = 131; 62.09%), followed by treatment ineffectiveness (n = 79; 37.44%). Drug selection (n = 116; 51.76%) and dispensing issues (n = 51; 22.77%) were the leading causes, with anti-infective drugs (n = 41; 35%) and antineoplastic agents (n = 24; 20.5%) most frequently implicated. Conclusion: DRPs were prevalent among pediatric patients with cancer, with treatment safety being the most significant issue and drug selection being the primary cause. Anti-infective drugs were most frequently involved in DRPs, followed by antineoplastic and immunomodulating agents.